Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations

Thomas Van den Broeck, Roderick C.N. van den Bergh, Erik Briers, Philip Cornford, Marcus Cumberbatch, Derya Tilki, Maria De Santis, Stefano Fanti, Nicola Fossati, Silke Gillessen, Jeremy P. Grummet, Ann M. Henry, Michael Lardas, Matthew Liew, Malcolm Mason, Lisa Moris, Ivo G. Schoots, Theodorus van der Kwast, Henk van der Poel, Thomas WiegelPeter Paul M. Willemse, Olivier Rouvière, Thomas B. Lam, Nicolas Mottet

Research output: Contribution to journalArticlepeer-review


Biochemical recurrence (BCR) after primary treatment of localized prostate cancer does not necessarily lead to clinically apparent progressive disease. To aid in prognostication, the European Association of Urology prostate cancer guidelines panel undertook a systematic review and successfully developed a novel BCR risk stratification system (groups with a low risk or high risk of BCR) based on disease and prostate-specific antigen characteristics. Patient summary: Following treatment to cure prostate cancer, some patients can develop recurrence of disease identified via a prostate-specific antigen blood test (ie, biochemical recurrence, or BCR). However, not every man who experiences BCR develops progressive disease (symptoms or evidence of disease progression on imaging). We conducted a review of the literature and developed a classification system for predicting which patients might progress to optimize treatment decisions. The EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guidelines panel recommends stratifying patients experiencing biochemical recurrence (BCR) after primary treatment for localized prostate cancer into EAU low-risk and high-risk BCR groups. Each patient's risk profile and life expectancy should be considered when discussing the benefits and toxicities of salvage treatments.

Original languageEnglish
JournalEuropean Urology Focus
Early online date24 Jun 2019
Publication statusPublished - 2019


  • Biochemical recurrence
  • European Association of Urology
  • Gleason score
  • Guidelines
  • Prognostic factors
  • Prostate cancer
  • PSA kinetics
  • Radical prostatectomy
  • Radiotherapy

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre


Dive into the research topics of 'Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations'. Together they form a unique fingerprint.

Cite this